Optimal dosing of galantamine in patients with mild or moderate alzheimers disease: Post hoc analysis of a randomized, double-blind, placebo-controlled trial

Drugs and Aging

Volumn 26, Issue 3, 2009, Pages 231-239

  Aronson, S ^a   Baelen, B R ^b   Kavanagh, S ^c   Schwalen, S ^d  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b SGS Medisearch International NV   (Belgium)

^c Health Economics   (Belgium)

^d UNIVERSITY OF WITTEN HERDECKE   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GALANTAMINE; PLACEBO; RAZADYNE ER; REMINYL PRC; UNCLASSIFIED DRUG;

AGED; AGITATION; ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ANOREXIA; ARTICLE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEMENTIA; DEPRESSION; DIARRHEA; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; FALLING; FATIGUE; FEMALE; HEADACHE; HUMAN; INJURY; MALE; NAUSEA; NERVOUSNESS; OPTIMAL DRUG DOSE; PERIPHERAL EDEMA; POST HOC ANALYSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RHINITIS; SIDE EFFECT; SOMNOLENCE; THORAX PAIN; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; VOMITING; WEIGHT REDUCTION;

AGED; ALZHEIMER DISEASE; CHOLINESTERASE INHIBITORS; COGNITION; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GALANTAMINE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 64749115858     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200926030-00004     Document Type: Article

References (28)

1. Ferri CP, Prince M, Brayne C, et al. Global prevalence of dementia: a Delphi consensus study. Lancet 2005; 366: 2112-7
2. Herbert LE, Scherr PA, Bienias JL, et al. Alzheimer disease in the US population: prevalence estimates using the 2000 census. Arch Neurol 2003; 60: 1119-22
3. Alzheimer's Association. Alzheimer's facts and figures 2007 [online]. Available from URL: http://www.alz.org/national/documents/report- alzfactsfigures2007.pdf [Accessed 2007 Jun 5]
4. American Psychiatric Association. Practice guidelines for the treatment of patients with Alzheimer's disease and other dementias late in life. Am J Psychiatry 1997; 154: 1-39
5. Geldmacher DS. Treatment guidelines for Alzheimer's disease: redefining perceptions in primary care. Prim Care Companion J Clin Psychiatry 2007; 9: 113-21
6. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. rev. Washington, DC: American Psychiatric Association, 2000
7. Forstl H, Kerz A. Clinical features of Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 1999; 249: 288-90 8. Bowie P, Branton T, Holmes J. Should the Mini Mental State Examination be used to monitor dementia treatment? Lancet 1999; 354: 1527-8
8. Galasko DR, Gould RL, Abramson IS, et al. Measuring cognitive change in a cohort of patients with Alzheimer's disease. Stat Med 2000; 19: 1421-32
9. Aricept/Aricept ODT [package insert]. Teaneck (NJ): Eisai Co., Ltd, 2006
10. Cognex [package insert]. Rosewell (GA): First Horizon Pharmaceutical Corp., 2002
11. Exelon [package insert]. East Hanover (NJ): Novartis Pharmaceuticals Corp., 2006
12. Reminyl [summary of product characteristics]. Dublin, Ireland: Shire Pharmaceuticals Ireland Limited, 2007
13. Reminyl XL [summary of product characteristics]. Dublin, Ireland: Shire Pharmaceuticals Ireland Limited, 2007
14. Razadyne ER/Razadyne [package insert]. Titusville (NJ): Ortho-McNeil Neurologics Inc., 2006
15. Ebixa [summary of product characteristics]. Valby, Denmark: H. Lundbeck A/S, 2005
16. Axura [summary of product characteristics]. Frankfurt, Germany: Merz Pharmaceuticals GmbH, 2005
17. Namenda [package insert]. St Louis (MO): Forest Pharmaceuticals Inc., 2005
18. Samochocki M, Zerlin M, Jostock R, et al. Galantamine is an allosterically potentiating ligand of the human α4/β2 nAChR. Acta Neurol Scand 2000; 176: 68-73
19. Maelicke A, Samochocki M, Jostock R, et al. Allosteric sensitization of nicotinic receptors by galantamine, a new treatment strategy for Alzheimer's disease. Biol Psychiatry 2001; 49: 279-88
20. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo controlled trial with a 6-month extension. Neurology 2000; 54: 2261-8
21. Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomized, controlled trial. J Neurol Neurosurg Psychiatry 2001; 71: 589-95
22. Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 2000; 54: 2269-76
23. Wilcock GK, Lillienfeld S, Gaens E, on behalf of the Galantamine International-1 Study Group. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: a multicentre randomized controlled trial. BMJ 2000; 321: 1445-9
24. Wilkinson D, Murray J, in collaboration with the Galantamine Research Group. Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2001; 16: 852-7
25. Rosen WG, Mohs RC, Davis KI. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141: 1356-64
26. Schneider LS, Olin JT, Doody RS, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study: Clinical Global Impression of Change. Alzheimer Dis Assoc Disorder 1997; 11 Suppl. 2: S22-32
27. Schwalen S, Van Baelen B, Kavanagh S. Comparison of the effects of 24mg versus 16mg galantamine in patients with moderate Alzheimer's disease [poster presentation]. 3rd Congress of the European Union of Geriatric Medicine Societies (EUGMS); 2004 Sep 15-18; Vienna
28. Davis KL, Mohs RC, Marlin D, et al. Cholinergic markers in elderly patients with early signs of Alzheimer disease. JAMA 1999 Apr 21; 281 (15): 1401-6